Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

BURLINGTON, N.C., April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.

Metadata
Provider: 
PR NewswirePR Newswire
Retrieved on: 
Monday, April 15, 2024
Information
Tags: 
Neurodegenerative disease, Nerve, Hospital, Blood, AFL, Brain, LH, Glioblastoma, GFAP, TBI, Alzheimer's disease, Disease, Injury, Astrocyte, Physician, Multiple sclerosis, Health, Traumatic brain injury, Biomarker, Glial fibrillary acidic protein, Medical imaging
Geotags: 
NORTH CAROLINA
Organisation: 
LABCORP, LABORATORY CORPORATION OF AMERICA, LABORATORY CORPORATION OF AMERICA HOLDINGS
Stock Symbol: 
NYSE:LH
Summary
Key Points: 
  • The new GFAP test – a first-of-its-kind test to be offered commercially nationwide – offers physicians a more efficient pathway to assess the presence and progression of neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, glioblastoma and injuries like traumatic brain injury (TBI).
  • The biomarker test also expands on Labcorp's comprehensive neurology portfolio, which includes biomarker tests for neurofilament light chain (NfL), pTau181, pTau217 and beta amyloid 42/40.
  • "The introduction of the GFAP biomarker test marks a significant milestone for Labcorp, extending our leadership in the rapidly accelerating field of blood-based biomarkers for neurodegenerative diseases," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer.
  • In the context of neurodegenerative disease or injury, astrocytes release GFAP into the blood, allowing brain injury and disease to be assessed through a simple blood draw.




Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries

BURLINGTON, N.C., April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.

The new GFAP test – a first-of-its-kind test to be offered commercially nationwide – offers physicians a more efficient pathway to assess the presence and progression of neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, glioblastoma and injuries like traumatic brain injury (TBI). The biomarker test also expands on Labcorp's comprehensive neurology portfolio, which includes biomarker tests for neurofilament light chain (NfL), pTau181, pTau217 and beta amyloid 42/40.

"The introduction of the GFAP biomarker test marks a significant milestone for Labcorp, extending our leadership in the rapidly accelerating field of blood-based biomarkers for neurodegenerative diseases," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "The breadth of our portfolio reflects our commitment to providing physicians with cutting-edge technology for the evaluation and treatment of neurodegeneration to enhance and improve patient care."

The GFAP test utilizes highly sensitive immunoassay technology to measure the presence of GFAP from a simple blood draw, which can be conducted in hospitals, a physician's office or any of Labcorp's more than 2,000 patient service centers across the country.

GFAP typically exists in the brain's support cells, known as astrocytes. In the context of neurodegenerative disease or injury, astrocytes release GFAP into the blood, allowing brain injury and disease to be assessed through a simple blood draw. GFAP has been widely studied as a valuable early-stage indicator of neurological damage.

For more information about the GFAP test and its applications in patient care, please visit https://www.labcorp.com/tests/484430/glial-fibrillary-acid-protein-gfap-serum

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-first-of-its-kind-test-for-early-indication-of-neurodegenerative-diseases-and-brain-injuries-using-a-blood-draw-302116574.html

SOURCE Labcorp



Copyright: 
2024 PR Newswire. All Rights Reserved.